Allena Pharmaceuticals
ALNA
ALNA was delisted on the 7th of September, 2022.
42 hedge funds and large institutions have $183M invested in Allena Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 10 increasing their positions, 9 reducing their positions, and 7 closing their positions.
29% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 7
11% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 9
8% more capital invested
Capital invested by funds: $169M → $183M (+$14.1M)
5% more funds holding
Funds holding: 40 → 42 (+2)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$3.7M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$712K |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$703K |
| 4 |
Millennium Management
New York
|
+$582K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$509K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$6.09M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.52M |
| 3 |
JP Morgan Chase
New York
|
-$1.35M |
| 4 |
Goldman Sachs
New York
|
-$171K |
| 5 |
DIM
DC Investments Management
Mclean,
Virginia
|
-$116K |
ALNA Hedge Fund Activity: Q1 2018 in Review
42 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Allena Pharmaceuticals (ALNA) for Q1 2018, worth a combined $183M — up 8.3% from $169M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new ALNA positions and 7 closed out — a net gain of 2 holders — while 10 added to existing stakes and 9 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $3.7M. The largest seller was Deerfield Management, exiting entirely with an estimated $6.09M sold.
- 42 institutional investors held Allena Pharmaceuticals (ALNA) as of Q1 2018, up from 40 in Q4 2017.
- Funds reported $183M of Allena Pharmaceuticals stock for Q1 2018, up 8.3% quarter-over-quarter.
- 9 funds opened new Allena Pharmaceuticals positions in Q1 2018 and 7 closed out, a net change of +2 holders.
- The largest Allena Pharmaceuticals buyer in Q1 2018 was Morgan Stanley, an estimated $3.7M added.
- The largest Allena Pharmaceuticals seller in Q1 2018 was Deerfield Management, an estimated $6.09M sold.
Based on aggregated 13F filings for Q1 2018.